NFKB1 and cancer: Thus, the α6β4 integrin/TNFAIP2/IQGAP1/Rac1 and α3β1/α11β1 integrins/Src/YAP pathways, as well as the αvβ3 integrin/YAP/AXL and αvβ3 integrin/KRAS/NF-κB pathways, may represent potential therapeutic targets to overcome drug resistance in cancer.